YESCARTA® is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.
YESCARTA® is indicated for the treatment of adult patients with relapsed or refractory (r/r) DLBCL and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.
UZ Leuven - Gasthuisberg
Herestraat, 49UZ Gent
Corneel Heymanslaan 10CHU de Liège
Avenue de l'hôpital, 1Contact:
Prof Dr Jo Caers: jo.caers@chu.ulg.ac.be
Dr Christophe Bonnet: christophe.bonnet@chuliege.be
Dr Claire Maquet: cmaquet@chuliege.be
Dr Céline Grégoire: celine.gregoire@chuliege.be
Cliniques universitaires Saint-Luc
Av. Hippocrate, 10Contact:
02 764 78 81Prof Dr Eric Van Den Neste: eric.vandenneste@saintluc.uclouvain.be
Dr Dachy Guillaume: guillaume.dachy@saintluc.uclouvain.be
Dr Sarah Bailly: sarah.bailly@saintluc.uclouvain.be
AZ Sint-Jan Brugge
Ruddershove 10CAR-T Coördinators:
Veronique Stockx
Veerle Peters
Kéhindé Louagie
HoST.verpleegkundigen@azsintjan.beInstitut Jules Bordet
Rue Meylemeersch, 90Contact:
Dr Marie Maerevoet: marie.maerevoet@hubruxelles.be
Dr Fulvio Massaro: fulvio.massaro@bordet.be
Prof Nathalie Meuleman: nathalie.meuleman@hubruxelles.be
Prof Virginie Dewilde: virginie.dewilde@hubruxelles.be
CHU UCL Namur
Avenue G.Thérasse, 1Contact:
081 42 38 33Prof Carlos Graux: carlos.graux@chuuclnamur.uclouvain.be
Dr Gilles Crochet: gilles.crochet@chuuclnamur.uclouvain.be
